{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:14:48Z","timestamp":1777626888585,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005421","name":"Guilan University of Medical Sciences","doi-asserted-by":"publisher","award":["96100202"],"award-info":[{"award-number":["96100202"]}],"id":[{"id":"10.13039\/501100005421","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.lfs.2019.116880","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T04:44:50Z","timestamp":1572583490000},"page":"116880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Rolipram optimizes therapeutic effect of bevacizumab by enhancing proapoptotic, antiproliferative signals in a glioblastoma heterotopic model"],"prefix":"10.1016","volume":"239","author":[{"given":"Sara","family":"Ramezani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasim","family":"Vousooghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Ramezani Kapourchali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh","family":"Yousefzadeh-Chabok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoheir","family":"Reihanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Mohammad","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Khodayari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Khodayari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lfs.2019.116880_bib1","doi-asserted-by":"crossref","first-page":"e000144","DOI":"10.1136\/esmoopen-2016-000144","article-title":"Hallmarks of glioblastoma: a systematic review","volume":"1","author":"N\u00f8r\u00f8xe","year":"2016","journal-title":"ESMO open"},{"issue":"2","key":"10.1016\/j.lfs.2019.116880_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol."},{"issue":"4","key":"10.1016\/j.lfs.2019.116880_bib3","first-page":"484","article-title":"Prognostic value of angiogenesis and survivin expression in patients with glioblastoma","volume":"26","author":"Tastekin","year":"2016","journal-title":"Turk Neurosurg"},{"issue":"4","key":"10.1016\/j.lfs.2019.116880_bib4","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ajpath.2012.06.030","article-title":"Mechanisms of glioma-associated neovascularization","volume":"181","author":"Hardee","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.lfs.2019.116880_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gendis.2016.11.003","article-title":"The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism","volume":"4","author":"Lv","year":"2017","journal-title":"Genes & Diseases"},{"issue":"3","key":"10.1016\/j.lfs.2019.116880_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1152\/physiol.00016.2013","article-title":"Apoptotic cell death under hypoxia","volume":"29","author":"Sendoel","year":"2014","journal-title":"Physiology"},{"issue":"11","key":"10.1016\/j.lfs.2019.116880_bib7","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA drug approval summary: bevacizumab (Avastin\u00ae) as treatment of recurrent glioblastoma multiforme","volume":"14","author":"Cohen","year":"2009","journal-title":"The Oncologist"},{"issue":"1","key":"10.1016\/j.lfs.2019.116880_bib8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3171\/2008.4.17492","article-title":"Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival","volume":"110","author":"Narayana","year":"2009","journal-title":"J. Neurosurg."},{"issue":"8","key":"10.1016\/j.lfs.2019.116880_bib9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1212\/01.wnl.0000208958.29600.87","article-title":"MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy","volume":"66","author":"Pope","year":"2006","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.lfs.2019.116880_bib10","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","article-title":"Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma","volume":"13","author":"Vredenburgh","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.lfs.2019.116880_bib11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/neuonc\/nop027","article-title":"Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice","volume":"12","author":"de Groot","year":"2010","journal-title":"Neuro Oncol."},{"issue":"15","key":"10.1016\/j.lfs.2019.116880_bib12","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/WNL.0b013e3181bc0184","article-title":"Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma","volume":"73","author":"Iwamoto","year":"2009","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.lfs.2019.116880_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2012.05.037","article-title":"VEGF inhibits tumor cell invasion and mesenchymal transition through a MET\/VEGFR2 complex","volume":"22","author":"Lu","year":"2012","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.lfs.2019.116880_bib14","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s12017-014-8324-8","article-title":"Direct effect of bevacizumab on glioblastoma cell lines in vitro","volume":"16","author":"Simon","year":"2014","journal-title":"NeuroMolecular Med."},{"issue":"1","key":"10.1016\/j.lfs.2019.116880_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jpedsurg.2012.10.016","article-title":"HIF-1\u03b1 activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts","volume":"48","author":"Hartwich","year":"2013","journal-title":"J. Pediatr. Surg."},{"key":"10.1016\/j.lfs.2019.116880_bib16","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.11771.1","article-title":"The role of tumor microenvironment in resistance to anti-angiogenic therapy","volume":"7","author":"Ma","year":"2018","journal-title":"F1000Research"},{"issue":"5","key":"10.1016\/j.lfs.2019.116880_bib17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.lfs.2019.116880_bib18","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ajpath.2017.01.010","article-title":"Hypoxia-mediated mechanisms associated with antiangiogenic treatment resistance in glioblastomas","volume":"187","author":"Mahase","year":"2017","journal-title":"Am. J. Pathol."},{"issue":"9","key":"10.1016\/j.lfs.2019.116880_bib19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/onc.2012.136","article-title":"Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF","volume":"32","author":"Pullamsetti","year":"2013","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.lfs.2019.116880_bib20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/leu.2015.302","article-title":"A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma","volume":"30","author":"Suhasini","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.lfs.2019.116880_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.tips.2011.02.015","article-title":"Treating brain tumors with PDE4 inhibitors","volume":"32","author":"Sengupta","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.lfs.2019.116880_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.lfs.2017.02.005","article-title":"Rolipram potentiates bevacizumab-induced cell death in human glioblastoma stem-like cells","volume":"173","author":"Ramezani","year":"2017","journal-title":"Life Sci."},{"issue":"8","key":"10.1016\/j.lfs.2019.116880_bib23","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s10495-017-1382-2","article-title":"Perifosine enhances bevacizumab-induced apoptosis and therapeutic efficacy by targeting PI3K\/AKT pathway in a glioblastoma heterotopic model","volume":"22","author":"Ramezani","year":"2017","journal-title":"Apoptosis"},{"issue":"3","key":"10.1016\/j.lfs.2019.116880_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4161\/cbt.80","article-title":"The type IV phosphodiesterase inhibitor rolipram induces expression inhibitors p21Cip1 and p27Kip1, resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells","volume":"1","author":"Chen","year":"2002","journal-title":"Cancer Biol. Ther."},{"issue":"23","key":"10.1016\/j.lfs.2019.116880_bib25","doi-asserted-by":"crossref","first-page":"7717","DOI":"10.1158\/1078-0432.CCR-08-0827","article-title":"Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression","volume":"14","author":"Goldhoff","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"9\u201310","key":"10.1016\/j.lfs.2019.116880_bib26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.lfs.2011.12.010","article-title":"Phosphodiesterase inhibitors control A172 human glioblastoma cell death through cAMP-mediated activation of protein kinase A and Epac1\/Rap1 pathways","volume":"90","author":"Moon","year":"2012","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.lfs.2019.116880_bib27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.18869\/nirp.bcn.8.4.325","article-title":"The role of protein kinase B signaling pathway in anti-cancer effect of rolipram on glioblastoma multiforme: an in vitro study","volume":"8","author":"Ramezani","year":"2017","journal-title":"Basic Clin. Neurosci."},{"key":"10.1016\/j.lfs.2019.116880_bib28","first-page":"2010","article-title":"Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells","author":"von Baumgarten","year":"2011","journal-title":"Clinical Cancer Research:clincanres. 1868"},{"issue":"2","key":"10.1016\/j.lfs.2019.116880_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.29046\/JHNJ.006.2.002","article-title":"Bevacizumab: a controversial agent against high-grade gliomas","volume":"6","author":"Salas","year":"2011","journal-title":"JHN J."},{"key":"10.1016\/j.lfs.2019.116880_bib30","series-title":"Questions Regarding the Optimal Use of Bevacizumab in Glioblastoma: a Moving Target","author":"Stupp","year":"2014"},{"key":"10.1016\/j.lfs.2019.116880_bib31","first-page":"1535","article-title":"Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition","author":"Rapisarda","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.lfs.2019.116880_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20021698","article-title":"PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization","volume":"370","author":"Houslay","year":"2003","journal-title":"Biochem. J."},{"issue":"12","key":"10.1016\/j.lfs.2019.116880_bib33","doi-asserted-by":"crossref","first-page":"a011148","DOI":"10.1101\/cshperspect.a011148","article-title":"The cyclic AMP pathway","volume":"4","author":"Sassone-Corsi","year":"2012","journal-title":"Cold Spring Harbor perspectives in biology"},{"issue":"34","key":"10.1016\/j.lfs.2019.116880_bib34","doi-asserted-by":"crossref","first-page":"23129","DOI":"10.1074\/jbc.M800478200","article-title":"A novel Epac-Rap-PP2A signaling module controls cAMP-dependent Akt regulation","volume":"283","author":"Hong","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.lfs.2019.116880_bib35","doi-asserted-by":"crossref","first-page":"12864","DOI":"10.1074\/jbc.M001492200","article-title":"Cyclic AMP inhibits Akt activity by blocking the membrane localization of PDK1","volume":"276","author":"Kim","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.lfs.2019.116880_bib36","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2004-01-0240","volume":"105","author":"Smith","year":"2005","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.lfs.2019.116880_bib37","doi-asserted-by":"crossref","first-page":"37242","DOI":"10.1074\/jbc.M105089200","article-title":"Cyclic AMP inhibits extracellular signal-regulated kinase and phosphatidylinositol 3-kinase\/Akt pathways by inhibiting Rap1","volume":"276","author":"Wang","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.lfs.2019.116880_bib38","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.lfs.2019.116880_bib39","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1242\/jcs.02724","article-title":"Protein kinase B\/Akt at a glance","volume":"118","author":"Fayard","year":"2005","journal-title":"J. Cell Sci."},{"issue":"3","key":"10.1016\/j.lfs.2019.116880_bib40","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.bbapap.2009.10.018","article-title":"Deregulated signalling networks in human brain tumours","volume":"1804","author":"Grzmil","year":"2010","journal-title":"Biochim. Biophys. Acta Protein Proteonomics"},{"issue":"5930","key":"10.1016\/j.lfs.2019.116880_bib41","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"issue":"34","key":"10.1016\/j.lfs.2019.116880_bib42","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1038\/sj.onc.1209608","article-title":"Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy","volume":"25","author":"Fulda","year":"2006","journal-title":"Oncogene"},{"issue":"20","key":"10.1016\/j.lfs.2019.116880_bib43","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1242\/jcs.00739","article-title":"Apoptosis-the p53 network","volume":"116","author":"Haupt","year":"2003","journal-title":"J. Cell Sci."},{"issue":"1","key":"10.1016\/j.lfs.2019.116880_bib44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-2407-12-58","article-title":"Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer","volume":"12","author":"Bisgin","year":"2012","journal-title":"BMC Canc."},{"issue":"41","key":"10.1016\/j.lfs.2019.116880_bib45","doi-asserted-by":"crossref","first-page":"5779","DOI":"10.1038\/sj.onc.1204742","article-title":"Dephosphorylated hypoxia-inducible factor 1\u03b1 as a mediator of p53-dependent apoptosis during hypoxia","volume":"20","author":"Suzuki","year":"2001","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.lfs.2019.116880_bib46","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/joim.12019","article-title":"VEGFA and tumour angiogenesis","volume":"273","author":"Claesson\u2010Welsh","year":"2013","journal-title":"J. Intern. Med."},{"issue":"2\u20133","key":"10.1016\/j.lfs.2019.116880_bib47","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mvr.2007.05.003","article-title":"Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization","volume":"74","author":"Fukumura","year":"2007","journal-title":"Microvasc. Res."},{"issue":"5706","key":"10.1016\/j.lfs.2019.116880_bib48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.lfs.2019.116880_bib49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fonc.2013.00211","article-title":"Vascular permeability and drug delivery in cancers","volume":"3","author":"Azzi","year":"2013","journal-title":"Frontiers in oncology"},{"issue":"13","key":"10.1016\/j.lfs.2019.116880_bib50","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/1078-0432.CCR-07-0278","article-title":"Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy","volume":"13","author":"Dickson","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"06","key":"10.1016\/j.lfs.2019.116880_bib51","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1055\/s-2007-1017435","article-title":"Results of a phase II study of the antidepressant effect of rolipram","volume":"17","author":"Zeller","year":"1984","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"10.1016\/j.lfs.2019.116880_bib52","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3109\/00498258809041693","article-title":"Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences","volume":"18","author":"Krause","year":"1988","journal-title":"Xenobiotica"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320519308070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320519308070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:43:05Z","timestamp":1777423385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320519308070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":52,"alternative-id":["S0024320519308070"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2019.116880","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rolipram optimizes therapeutic effect of bevacizumab by enhancing proapoptotic, antiproliferative signals in a glioblastoma heterotopic model","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2019.116880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116880"}}